Can two added drugs outsmart pancreatic Cancer's defenses?
NCT ID NCT05077800
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 35 times
Summary
This study tests whether adding two experimental drugs (elraglusib and losartan) to standard chemotherapy (FOLFIRINOX) can prevent metastatic pancreatic cancer from becoming resistant to treatment. About 70 adults with untreated, advanced pancreatic cancer are participating. The goal is to see if the combination improves how long the cancer stays under control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Charlestown, Massachusetts, 02129, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Washington School of Medicine
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.